Adalimumab Reduces Extraintestinal Manifestations in Patients With Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies

Advances in Therapy - United States
doi 10.1007/s12325-018-0678-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2018English

Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Extraintestinal Manifestations of the Eye in Patients With Inflammatory Bowel Diseases

Medicinski Casopis
Medicine
2017English

Adalimumab for Endoscopic and Histopathological Mucosal Healing in Paediatric Patients With Moderate to Severe Crohn’s Disease

Przeglad Gastroenterologiczny
Gastroenterology
2017English

Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2018English

Immunogenicity Negatively Influences the Outcome of Adalimumab Treatment in Crohn’s Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2008English

Extraintestinal Manifestations of Ulcerative Colitis

2011English

P577 Joint Manifestations as a Form of Onset in Crohn’s Disease

2019English

Primary Cutaneous Nocardiosis in a Patient Taking Adalimumab Therapy for Crohn’s Disease

Kansas Journal of Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy